Cryo-Cell International, Inc. (CCEL) is a small-cap healthcare company operating in the niche field of cord blood and cord tissue banking. Founded in 1989 and headquartered in Oldsmar, Florida, the company is best known as the world's first private cord blood bank and describes itself as having separated and stored stem cells for family use as early as 1992. Investors pay attention to CCEL because it sits at the intersection of a recurring-revenue services business and the longer-term growth story of regenerative medicine. When screening for comparable names in this space, I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Cryo-Cell International's company overview centers on the collection, processing, and long-term cryogenic (frozen) storage of newborn stem cells. After a baby is born, families can arrange for the blood and tissue from the umbilical cord to be collected and sent to Cryo-Cell's laboratory, where it is processed, tested, and preserved in liquid nitrogen for potential future medical use. The company markets these services directly to expectant parents and through obstetricians, pediatricians, and other healthcare professionals.
The business model is built around a recurring-fee structure. Families typically pay an initial processing and testing fee, followed by annual storage fees to keep their specimens preserved. This creates a relatively stable, subscription-like revenue stream, because most of the company's revenue comes from processing and storage fees rather than one-time transactions.
Cryo-Cell reports its operations in three primary segments. The largest is its umbilical cord blood and cord tissue stem cell service, which handles cryopreservation for family use. The second is the PrepaCyte-CB segment, which manufactures a proprietary cord blood processing technology for which the company holds exclusive rights. The third is public cord blood banking, conducted in partnership with Duke University, which has supplied cord blood for transplants.
Within its industry, Cryo-Cell's market position is anchored by its first-mover history and its accreditation and regulatory profile. The company states that its facility is registered with the U.S. Food and Drug Administration (FDA), compliant with current good manufacturing practice (cGMP) and good tissue practice (cGTP) standards, and licensed in all states that require licensure. It is accredited by AABB and was among the first U.S. private cord blood banks to receive FACT accreditation, a rigorous quality standard for cellular therapy facilities.
The company has also sought to broaden its footprint beyond storage. In February 2021, it entered an exclusive collaborative license agreement with Duke University, granting access to certain intellectual property, proprietary processes, and clinical data related to cord blood and cord tissue developed at Duke's Marcus Center for Cellular Cures. This positions Cryo-Cell to explore future clinical applications in areas such as autism, cerebral palsy, and other conditions. From what I see, this partnership stands out as a key differentiator worth monitoring over time.
Cryo-Cell's financial profile reflects a compact, services-oriented operation. The company employs fewer than 100 people and reports annual revenue in the range of roughly $31 million to $32 million in recent fiscal years, with the substantial majority of that revenue derived from processing and storage fees. Its shares trade on the NYSE American exchange, and the company has historically maintained a relatively small public float.
Investors tend to follow CCEL primarily for its exposure to the regenerative medicine and stem cell therapy theme. As a pioneer in private cord blood banking, the company holds a recognizable brand in a specialized field. Its recurring annual storage fees offer a degree of revenue predictability, while its exclusive PrepaCyte-CB technology and Duke University partnership represent potential long-term growth options beyond basic storage services.
For investors interested in small-cap healthcare names with a differentiated, defensible niche, Cryo-Cell offers a direct way to gain exposure to the growing awareness of stem cell preservation without investing in a diversified biopharmaceutical portfolio.
Investing in CCEL carries several risks that investors should understand. The company operates in a competitive and highly regulated industry, where demand for private cord blood banking can be influenced by birth rates, consumer confidence, healthcare costs, and medical guidance about the utility of stored stem cells. As a small-cap company, it has a limited public float and relatively low trading liquidity, which can contribute to price volatility.
The company's financial profile has also shown sensitivity to changes in sales trends and inventory valuations. In its fiscal year ended November 30, 2025, Cryo-Cell reported a net loss, partly driven by a non-cash impairment charge, and it has received continued listing notices from the NYSE American related to compliance standards. The company has reported steps to regain compliance, but its listing status and dividend policy have fluctuated, underscoring the importance of monitoring regulatory and financial developments. The regenerative medicine applications tied to its Duke University partnership also remain early-stage and may take years to develop, if at all.
In my own research, I frequently rely on Tickeron's AI Screener to efficiently compare opportunities like CCEL against thousands of other stocks and ETFs. The platform lets me apply filters for technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, and price patterns, helping surface ideas that fit specific strategies without reviewing each security individually. This approach has become a regular part of how I build and refine watchlists for niche healthcare names.
Cryo-Cell International (CCEL) occupies a distinctive position as the world's first private cord blood bank, combining a recurring-fee storage business with proprietary processing technology and a university research partnership. Its small size, regulatory exposure, and early-stage clinical ambitions make it a higher-risk, specialized investment within the broader healthcare sector. For investors who follow the regenerative medicine theme and understand the risks of small-cap equities, CCEL remains a notable name to watch.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CCEL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 43 of 49 cases where CCEL's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 65 cases where CCEL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
CCEL moved above its 50-day moving average on October 16, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CCEL crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Following a +10.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where CCEL advanced for three days, in 150 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 79 of 97 cases where CCEL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
The 10-day RSI Indicator for CCEL moved out of overbought territory on November 03, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 26 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on November 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CCEL as a result. In 107 of 119 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for CCEL turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In 45 of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CCEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-2.220) is normal, around the industry mean (204.532). P/E Ratio (-15.774) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (2.680) is also within normal values, averaging (2.498). Dividend Yield (0.123) settles around the average of (0.154) among similar stocks. P/S Ratio (1.141) is also within normal values, averaging (2.688).
The Tickeron SMR rating for this company is 12 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. CCEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 88 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CCEL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry HospitalNursingManagement